19 Tips for Finding...
Health Care: Drugs
Discovery Laboratories Inc. (DSCO: NASDAQ)
$2.50 -0.02 | -0.79%
06/04/12 - 09:34 AM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.06 | 0.58 | 0.98 |
| Price to Sales (TTM) | 543.76 | 4.62 | 1.42 |
| Price to Book (MRQ) | 2.59 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | 2.59 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -4.20 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -4.70 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | -100.00 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | n.a. | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | n.a. | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -51.58 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 3.80 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 3.80 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | 0.01 | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | n.a. | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | n.a. | 83.50 | 47.70 |
| EBITD Margin (TTM) | n.a. | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -3,083.70 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | n.a. | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -135.04 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -47.00 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -103.00 | 2.20 | 2.50 |
| Return on Investment (TTM) | -64.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -173.00 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 2,871.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -387,771.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | n.a. | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.00 | 0.40 | 0.40 |
Portfolios with DSCO
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- UserSmall Cap Stocks
- UserKJP Spring Break
- Userjet189 Portfolio 1
- Uservolume spike
- Usermoon_in_mood Portfolio 1
- UserDtech Portfolio 1
- UserLizann
- UserBNunnally Portfolio 1
- Usershaldar Portfolio 1
Latest DSCO Headlines from TheStreet
- 5 Stocks Under $10 Poised for Upside 04.27.12 | 11:04 am
- For Biotech Takeovers, Timing is Key 04.04.12 | 06:04 am
- For Biotech, 'Fail' is Making a Big Comeback 03.12.12 | 08:03 am
- Biotech Stock Mailbag: Oncothyreon, Amag, Keryx Hate Mail 03.09.12 | 05:03 am
- Market Preview: The Bulls Finally Blink (Correct) 03.06.12 | 10:03 pm
- Pandora, Discovery Labs: After-Hours Trading (Update 1) 03.06.12 | 08:03 pm
- The Next Big Thing in Biotech: Discovery Labs
03.02.12 | 06:03 am - Biotech Stock Mailbag: Cyclacel Fallout, the Skinny on Vivus, Celldex's Crash 03.02.12 | 05:03 am
- These Drugs Stocks Will Win FDA Approval 02.16.12 | 12:02 pm
- Play TheStreet's FDA Drug-Approval Contest 01.23.12 | 08:01 am
Press Releases for DSCO
- Pharmacoeconomic Analysis Shows SURFAXIN® May Reduce Hospital Cost Associated With Reintubation In Premature Infants - PR Newswire 05.01.12 | 07:05 am
- Media Alert: Discovery Labs To Hold Conference Call To Discuss FDA Approval Of SURFAXIN® (lucinactant) - PR Newswire 03.07.12 | 07:03 am
- Discovery Labs Announces FDA Approval Of SURFAXIN® (lucinactant) For Prevention Of Respiratory Distress Syndrome - PR Newswire 03.06.12 | 04:03 pm
- Discovery Labs Signs Manufacturing Agreement For AFECTAIR® - PR Newswire 02.08.12 | 07:02 am
- Discovery Labs Cleared To Market AFECTAIR In U.S. - PR Newswire 02.02.12 | 07:02 am
- New Study Shows AFECTAIR® Significantly Improved Delivery Of Nitric Oxide Under Simulated Neonatal Ventilatory Conditions - PR Newswire 12.06.11 | 08:12 am
- Discovery Labs Releases New AFECTAIR⢠Performance Data Presented At The American Association For Respiratory Care Annual Meeting - PR Newswire 11.08.11 | 08:11 am
- New Study Shows Neonatologists And Parents Of NICU Infants Share Concern Regarding Newborn Exposure To Animal-Derived Medications - PR Newswire 10.18.11 | 07:10 am
- Discovery Labs Notified Of PDUFA Date For SURFAXIN® - PR Newswire 09.28.11 | 12:09 pm
- Discovery Labs Submits SURFAXIN® Complete Response To FDA - PR Newswire 09.06.11 | 07:09 am
Partner Headlines for DSCO
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Bio-Pharma Drug Approval Watch List: Final Results Plus One To Watch - Seeking Alpha 03.30.12 | 09:03 am
- Discovery Labs Down 17% After Public Offering Announcement - Benzinga 03.16.12 | 09:03 am
- Company News for March 8, 2012 - Corporate Summary - Zacks 03.08.12 | 10:03 am
- Discovery Labs Up 33% After Surfaxin Approved by the FDA - Benzinga 03.07.12 | 09:03 am
- Discovery Labs Announces FDA Approval of SURFAXIN for Prevention of Respiratory Distress Syndrome - Benzinga 03.06.12 | 04:03 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 11.15.11 | 09:11 am
- UPDATE 1-Discovery Labs' cystic fibrosis drug gets orphan status - Reuters 11.01.10 | 08:11 am
- UPDATE 1-Discovery Labs lung drug disappoints in mid-stage trial - Reuters 06.09.10 | 08:06 am
- FDA, Clinical Trial News: Discovery Labs, Hospira, Javelin Pharma - Seeking Alpha 05.20.10 | 06:05 am
